MedPath

TRIUMEQ

TRIUMEQ

Approved
DIN Number

02430932

Drug Class

Human

Market Date

Oct 22, 2014

Company
HC

viiv healthcare ulc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02430932
AIG Number0355990001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription
A
ATC Code
J05AR13 LAMIVUDINE, ABACAVIR AND DOLUTEGRAVIR
Product Specifications
Dosage FormTablet
Route of AdministrationOral
AHFS Classification08:18.08.20
Health Canada Classification

ACTIVE INGREDIENTS (3)

ABACAVIR (ABACAVIR SULFATE)Active
Strength: 600 MG
Monograph: ABACAVIR (ABACAVIR SULFATE)
DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM)Active
Strength: 50 MG
Monograph: DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM)
LAMIVUDINEActive
Strength: 300 MG
Monograph: LAMIVUDINE

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.